This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HyperprolactinemiaHyperprolactinemiaAboutSymptomsTest Results InterpretationTreatmentManagementMenopauseMenopauseDiagnosingSymptomsManagementTreatmentSupport & ResourcesSupport & ResourcesVideosMaterials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

About Hyperprolactinaemia Overview 

Hyperprolactinaemia is a condition characterized by an elevated level of prolactin in the blood.1 The consequences of this imbalance are varied but most commonly lead to hypogonadism, resulting in infertility, low libido, decreased bone mass, and, in women, oligomenorrhoea and/or amenorrhoea.1

Hyperprolactinaemia occurs more frequently in women than men.1
The prevalence of hyperprolactinaemia varies based on the population under investigation.
It is:1-3
• 0.4% in the general population
• 9%-17% in women with reproductive diseases
• 16%-30% in women with infertility
• ~ 5% among men who present with impotence or infertility

Pathophysiology

Prolactin, which is synthesized by the pituitary gland, primarily functions to stimulate and maintain the production of breast milk during pregnancy and breastfeeding.1,4
When prolactin levels are elevated in either women or men, gonadotropin-releasing hormone (GnRH) secretion is inhibited and gonadal function is affected, ultimately leading to infertility.4,5

Adapted from Kaiser UK, 2012.6

Etiology

Hyperprolactinaemia can arise from pharmacologic, pathologic, physiologic, and idiopathic causes.1

Prolactinomas are the most common cause of hyperprolactinaemia, which account for approximately 40% of all pituitary tumors.7

Effects of Certain Medications

It is important to be aware that several different types of medications and drugs can cause increased serum prolactin levels.

Adapted from Vilar L., et al and Peña KS., et al.

Please note some of these medications are not available in the UK

Estring (estradiol hemihydrate) prescribing information can be found here
Premarin (oestrogens, conjugated) prescribing information can be found here
Premique (medroxyprogesterone acetate oestrogens, conjugated) prescribing information can be found here​​​​​​

​References

Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168-175.Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. ArqBras Endocrinol Metabol. 2014;58(1):9-22.Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169(6):575-815.Endocrine Society. The Hormone Foundation's patient guide to hyperprolactinemia diagnosis and treatment. https://academic.oup.com/jcem/article/96/2/35A/2709499. Accessed April 2022.Marieb EN, Hoehn K. Chapter 28: Pregnancy and human development. In: Human Anatomy & Physiology, 11th ed. Hoboken, NJ: Pearson Education; 2018. Kaiser UB. Hyperprolactinemia and infertility: new insights. J Clin Invest. 2012;122(10):3467-3468.Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.Peña KS, Rosenfeld JA. Evaluation and treatment of galactorrhea. Am Fam Physician. 2001;63(9):1763- 1670.
PP-UNP-GBR-0580. June 2022
Identifying Common Symptoms

Understand what signs to look for and explore two patient case studies

Learn more Loading
Interpreting Test Results

Recognise which tests to order and what the results indicate​​​​

Learn more Loading
Selecting Treatment based on Guidelines

Determine therapy based on clinical and patient factors

Learn more Loading
Monitoring and Management

Learn how to tailor therapy based on follow-up testing

Learn more Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​